Prospects for the use of differentiation‐modulating agents as adjuvant of photodynamic therapy for proliferative dermatoses

Current interest in photodynamic therapy (PDT) in dermatology stems from its recognized success in dermatological oncology, straightforward approach, easy accessibility and low cost. PDT is a photochemistry‐based modality in which a light‐activated photosensitizer (PS) destroys tissue through oxygen‐dependent and ‐independent mechanisms. Although PDT has been used in dermatology for several decades, its application has still not extended significantly into the routine management of neoplastic and proliferative dermatoses because of continuing issues with the selectivity of the PS for affected tissues. This review analyzes prospects for optimization of PDT for the management of dermatoses with defects in keratinocyte proliferation/differentiation, and discusses the use of differentiating agents that redirect metabolic utilization within cells and lead to high levels of PS accumulation.

[1]  T. Hasan,et al.  Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells , 2006, British Journal of Cancer.

[2]  P. Beattie,et al.  Lack of efficacy and tolerability of topical PDT for psoriasis in comparison with narrowband UVB phototherapy , 2004, Clinical and experimental dermatology.

[3]  K. König,et al.  Photodynamic therapy in psoriasis: suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo , 2004, Archives of Dermatological Research.

[4]  E. Atillasoy,et al.  Methotrexate induces differentiation of human keratinocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Eun-So Lee,et al.  Topical 5‐aminolaevulinic acid photodynamic therapy for intractable palmoplantar psoriasis , 2007, The Journal of dermatology.

[6]  J K Hoober,et al.  Photodynamic immunopotentiation: in vitro activation of macrophages by treatment of mouse peritoneal cells with haematoporphyrin derivative and light. , 1991, European journal of cancer.

[7]  R. Szeimies.  Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. , 2007, Dermatologic clinics.

[8]  A. Ros,et al.  Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5‐aminolaevulinic acid photodynamic therapy , 2005, Photodermatology, photoimmunology & photomedicine.

[9]  David J Goldberg,et al.  A Review of Laser and Photodynamic Therapy for the Treatment of Nonmelanoma Skin Cancer , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[10]  T. Hasan,et al.  Parasiticidal effect of δ‐aminolevulinic acid‐based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells , 2007, Experimental dermatology.

[11]  E. De Clercq,et al.  Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. , 1999, Biochemical pharmacology.

[12]  H Moseley,et al.  Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group , 2002, The British journal of dermatology.

[13]  T. Hasan,et al.  Vitamin D enhances ALA-induced protoporphyrin IX production and photodynamic cell death in 3-D organotypic cultures of keratinocytes. , 2007, The Journal of investigative dermatology.

[14]  J. Rao,et al.  Photodynamic therapy for actinic keratoses. , 2007, Dermatologic clinics.

[15]  S. Ross,et al.  Retinoic acid and methotrexate specifically increase PHA‐E‐lectin binding to a 67‐kDa glycoprotein in LA‐N‐1 human neuroblastoma cells , 1995, International journal of cancer.

[16]  J. Norton,et al.  Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. , 1990, Journal of the National Cancer Institute.

[17]  Z. Malik,et al.  Treatment of viral infections with 5‐aminolevulinic acid and light , 1997, Lasers in surgery and medicine.

[18]  T. Hasan,et al.  Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. , 1998, British Journal of Cancer.

[19]  E. Jeffes,et al.  Cytotoxic and immunologic effects of methotrexate in psoriasis. , 1990, The Journal of investigative dermatology.

[20]  T. Hasan,et al.  Targeting of Sebocytes by Aminolevulinic Acid-dependent Photosensitization , 2006, Photochemistry and photobiology.

[21]  E. De Clercq,et al.  Potent differentiation-inducing properties of the antiretroviral agent 9-(2-phosphonylmethoxyethyl) adenine (PMEA) in the rat choriocarcinoma (RCHO) tumor cell model. , 1998, Biochemical pharmacology.

[22]  R. Gallo,et al.  Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate. , 1981, Journal of the National Cancer Institute.

[23]  P. Skehan,et al.  Morphological differentiation of human choriocarcinoma cells induced by methotrexate. , 1979, Cancer research.

[24]  P. M. Schwartz,et al.  Keratinocytes differentiate in response to inhibitors of deoxyribonucleotide synthesis. , 1995, Journal of dermatological science.

[25]  Donald P. McDonnell,et al.  International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors , 2006, Pharmacological Reviews.

[26]  P. V. D. van de Kerkhof,et al.  Heterogeneity of fluorescence in psoriasis after application of 5‐aminolaevulinic acid: an immunohistochemical study , 2006, The British journal of dermatology.

[27]  J D Baxter,et al.  The nuclear hormone receptor gene superfamily. , 1995, Annual review of medicine.

[28]  I. Stender,et al.  Treatment of recalcitrant verrucae by photodynamic therapy with topical application of δ‐aminolaevulinic acid , 1996, Clinical and experimental dermatology.

[29]  T. Hasan,et al.  Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells , 2002, British Journal of Cancer.

[30]  T. Hasan,et al.  The potential for photodynamic therapy in the treatment of localized infections. , 2005, Photodiagnosis and photodynamic therapy.

[31]  Christian Gluud,et al.  Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial , 2000, The Lancet.

[32]  H. Kohno,et al.  Coproporphyrinogen oxidase. Purification, molecular cloning, and induction of mRNA during erythroid differentiation. , 1993, The Journal of biological chemistry.

[33]  L. Braathen,et al.  Topical photodynamic therapy in verrucae. A pilot study. , 1995, Dermatology.

[34]  Wei Li,et al.  5-Aminolaevulinic acid-mediated photodynamic therapy in multidrug resistant leukemia cells. , 2001, Journal of photochemistry and photobiology. B, Biology.

[35]  M. Landthaler,et al.  Photodynamic therapy in dermatology – an update , 2005, Photodermatology, photoimmunology & photomedicine.

[36]  Ann-Marie Wennberg,et al.  Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. , 2007, Journal of the American Academy of Dermatology.

[37]  P. V. D. van de Kerkhof,et al.  A placebo‐controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5‐aminolaevulinic acid‐photodynamic therapy in patients with psoriasis , 2006, The British journal of dermatology.

[38]  T. Hasan,et al.  A mechanistic study of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis. , 2007, The Journal of investigative dermatology.

[39]  A. Oseroff,et al.  Photodynamic therapy for nonmelanoma skin cancers. Current review and update. , 2003, Molecular immunology.

[40]  J. Kennedy,et al.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. , 1990, Journal of photochemistry and photobiology. B, Biology.

[41]  C. Morton.  Methyl aminolevulinate (Metvix®) photodynamic therapy - practical pearls , 2003, The Journal of dermatological treatment.

[42]  P. Lehmann.  Methyl aminolaevulinate–photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer , 2007, The British journal of dermatology.

[43]  T. Tagawa,et al.  Griseofulvin enhances the effect of aminolevulinic acid-based photodynamic therapy in vitro. , 2006, Photomedicine and laser surgery.

[44]  H. Meffert,et al.  [Photodynamic therapy of psoriasis palmaris et plantaris using a topically applied hematoporphyrin derivative and visible light]. , 1989, Dermatologische Monatschrift.

[45]  A Tanew,et al.  Topical aminolaevulinic acid‐based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer‐blinded study , 2005, The British journal of dermatology.

[46]  A. M. del C. Batlle,et al.  Enhancement of aminolevulinic acid based photodynamic therapy by adriamycin. , 1997, Cancer letters.

[47]  Z. Malik,et al.  Protoporphyrin biosynthesis in Melanoma B16 cells stimulated by 5‐aminolevulinic acid and chemical inducers: Characterization of photodynamic inactivation , 2007, International journal of cancer.

[48]  D. Doiron,et al.  Photodynamic Therapy for Nonmelanoma Skin Cancer , 1989, Facial plastic surgery : FPS.

[49]  I. Stender,et al.  Recalcitrant hand and foot warts successfully treated with photodynamic therapy with topical 5‐aminolaevulinic acid: a pilot study , 1999, Clinical and experimental dermatology.

[50]  T. Hasan,et al.  Photodynamic therapy against intracellular pathogens: Problems and potentials , 2006 .

[51]  H. Lui,et al.  Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques. , 2002, The Journal of investigative dermatology.

[52]  Edward V. Maytin,et al.  Nuclear transcription factors: a new approach to enhancing cellular responses to ALA-mediated photodynamic therapy , 2006, SPIE BiOS.

[53]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[54]  H. Wulf,et al.  Photodynamic therapy of recalcitrant warts with 5-aminolevulinic acid: a retrospective analysis. , 1999, Acta dermato-venereologica.

[55]  T. Hasan,et al.  Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation , 2007, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[56]  C. Whitehurst,et al.  Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. , 2001, Archives of dermatology.

[57]  B W Henderson,et al.  Role of cytokines in photodynamic therapy-induced local and systemic inflammation , 2003, British Journal of Cancer.

[58]  P. Chung,et al.  Recalcitrant palmoplantar pustular psoriasis successfully treated with topical 5‐aminolaevulinic acid photodynamic therapy , 2005, Clinical and experimental dermatology.

[59]  M. Landthaler,et al.  Disappointing results and low tolerability of photodynamic therapy with topical 5‐aminolaevulinic acid in psoriasis. A randomized, double‐blind phase I/II study , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[60]  M. Landthaler,et al.  Non-oncologic indications for ALA-PDT , 2002, The Journal of dermatological treatment.

[61]  M. Darmon,et al.  1,25-Dihydroxyvitamin D3 stimulates specifically the last steps of epidermal differentiation of cultured human keratinocytes. , 1991, Differentiation; research in biological diversity.